Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)

Name: Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
Published: 2014
License: Public Domain

Celgene · 2014

ClinicalTrials.gov · Datasets · License: Public Domain · 2014

Open Source ↗

neoplasms

pancreatic neoplasms, digestive system neoplasms, neoplasms by site, neoplasms, endocrine gland neoplasms, pancreatic diseases, digestive system diseases, endocrine system diseases, gemcitabine, antimetabolites, antineoplastic, resectable pancreatic cancer, resected

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 851350
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.